Synthomer (LON:SYNT) Downgraded to Hold Rating by Berenberg Bank

Berenberg Bank lowered shares of Synthomer (LON:SYNTFree Report) to a hold rating in a report released on Wednesday,Digital Look reports. They currently have GBX 150 ($1.94) price target on the stock, down from their previous price target of GBX 230 ($2.98).

Synthomer Stock Performance

LON SYNT opened at GBX 118.40 ($1.53) on Wednesday. The company’s 50 day simple moving average is GBX 139.31 and its two-hundred day simple moving average is GBX 170.80. The company has a debt-to-equity ratio of 78.27, a current ratio of 1.90 and a quick ratio of 0.97. Synthomer has a 1 year low of GBX 114 ($1.47) and a 1 year high of GBX 338 ($4.37). The stock has a market capitalization of £194.15 million, a PE ratio of -2.37, a P/E/G ratio of -0.17 and a beta of 1.79.

Synthomer (LON:SYNTGet Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The company reported GBX (3.50) (($0.05)) earnings per share (EPS) for the quarter. Synthomer had a negative return on equity of 7.52% and a negative net margin of 4.40%. Analysts predict that Synthomer will post 12.962963 earnings per share for the current fiscal year.

About Synthomer

(Get Free Report)

Synthomer plc operates as a specialty chemicals company in the United Kingdom and internationally. It operates through five segments: Performance Elastomers, Functional Solutions, Industrial Specialities, Acrylate Monomers, and Adhesive Technologies. The company offers adhesives, including PSA labels, packaging and specialty tapes, saturants, release coatings, wood working, wet glues, hygiene and contact adhesives, packaging and assembly hot melt adhesives; coatings products such as architectural, masonry, intumescent, metal, wood, soil releases, blinders, ink receptive, polyester for powder coatings, SYNTHOMER NX for coalescing agents, and SYNOLOX BEPF for glycol.

Further Reading

Receive News & Ratings for Synthomer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthomer and related companies with MarketBeat.com's FREE daily email newsletter.